KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Treasury Shares (2016 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Treasury Shares for 14 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 1445.28% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $4.7 million, up 1445.28%, while the annual FY2025 figure was $4.7 million, 1445.28% up from the prior year.
  • Treasury Shares hit $4.7 million in Q4 2025 for Ionis Pharmaceuticals, up from $307000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.7 million in Q4 2025 and bottomed at $59000.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $2.2 million, with a median of $2.8 million recorded in 2022.
  • Year-over-year, Treasury Shares plummeted 97.51% in 2021 and then soared 4588.14% in 2022.
  • Ionis Pharmaceuticals' Treasury Shares stood at $59000.0 in 2021, then skyrocketed by 4588.14% to $2.8 million in 2022, then increased by 17.1% to $3.2 million in 2023, then tumbled by 90.52% to $307000.0 in 2024, then soared by 1445.28% to $4.7 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $4.7 million, $307000.0, and $3.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.